March 20th 2025
Azer-cel elicited strong and durable responses in patients with heavily pretreated relapsed/refractory DLBCL in a phase 1b trial.
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Approves Polatuzumab Vedotin/R-CHP Combo in Previously Untreated DLBCL
April 19th 2023Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone following the FDA’s approval of the regimen.
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert Says
April 19th 2023Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Real-World Data Highlight Need for Clinically Practical MCL Therapies
April 5th 2023Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.
FDA Grants Orphan Drug Designation to Tirabrutinib in Primary CNS Lymphoma
March 29th 2023Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
FDA ODAC Votes in Favor of Polatuzumab Vedotin in Previously Untreated DLBCL
March 10th 2023Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.